| ²é¿´: 744 | »Ø¸´: 2 | |||
Burns_Traumaгæ (³õÈëÎÄ̳)
|
[½»Á÷]
×îÐÂÎÄÕ¡ª¡ª¾Û½¹ÉÕÉË´´ÉË»¼Õßŧ¶¾Ö¢£¨Sepsis£©µÄÑо¿ ÒÑÓÐ2È˲ÎÓë
|
|
ÓйØÉÕÉË¡¢´´É˲¡ÈËŧ¶¾Ö¢µÄÔ¤²â¡¢ÖÎÁÆ·½ÃæµÄ×îÐÂÎÄÕ£º 1. Advances in sepsis-associated liver dysfunction ŧ¶¾Ö¢Ïà¹Ø¸Î¹¦Äܲ»È«Ñо¿½øÕ¹ ÕªÒª£º×îÐÂÑо¿±íÃ÷£¬¸Î¹¦Äܲ»È«·¢ÉúÓÚŧ¶¾Ö¢ÔçÆÚ¡£Å§¶¾Ö¢Ïà¹Ø¸Î¹¦Äܲ»È«·¢²¡»úÖÆ°üÀ¨3·½Ã棺ÌåÑ»·ºÍ΢ѻ·¹¦ÄÜÎÉÂÒ¡¢Ï¸¾úºÍÄÚ¶¾ËصÄÈëÇÖ¡¢Ï¸°ûÒò×ÓºÍÑ×Ö¢½éÖʵļ¤»î¡£Éæ¼°µÄ¸Îϸ°û°üÀ¨£º¿Ý·ñÊÏϸ°û¡¢¸Îϸ°ûºÍ¸Îñ¼×´ÄÚÆ¤Ï¸°û¡£´ËÍ⣬¼¤»îµÄÖÐÐÔÁ£Ï¸°ûÏò¸ÎÔà=£¬¼Ì¶øÊÍ·ÅøÀàÎïÖʺÍÑõ×ÔÓÉ»ù£¬½øÒ»²½¼Ó¾çÁ˸ÎÔàËðÉË¡£ÁÙ´²ÉÏŧ¶¾Ö¢Ïà¹Ø¸Î¹¦Äܲ»È«¿É´óÖ·ÖΪ2ÖÖ£ºÈ±ÑõÐÔ¸ÎÑ׺ͻÆð㣬ºóÕßÔÚŧ¶¾Ö¢ÖиüΪ³£¼û¡£Å§¶¾Ö¢ÍíÆÚ£¬¶àÆ÷¹Ù¹¦ÄÜÕϰ³ÖÐø½øÕ¹¿É³öÏÖ¸ÎË¥½ß¡£Õë¶Ôŧ¶¾Ö¢¸Î¹¦Äܲ»È«£¬ÉÐÎÞÌØÒìÐÔÖÎÁÆ¡£Ä¿Ç°ÖÎÁÆ´ëÊ©Ö÷ҪΪȥ³ý¸ÐȾÔîºÍ¶ÔÑÏ֨ŧ¶¾Ö¢µÄÖÎÁÆ¡£¸üºÃµÄÈÏʶŧ¶¾Ö¢¸ÎÔà·´Ó¦µÄ²¡ÀíÉúÀí¹ý³Ì£¬ÓÐÍû½øÒ»²½Ìá¸ß»¼ÕßÉú´æÂÊ¡£ http://www.burnstrauma.com/article.asp?issn=2321-3868;year=2014;volume=2;issue=3;spage=97;epage=105;aulast=Wang 2. Prediction of sepsis in trauma patients ´´É˲¡ÈËŧ¶¾Ö¢µÄÔ¤²â ÕªÒª£º´´ÉËÔÚÊÀ½ç·¶Î§ÄÚÈÔÈ»ÊÇÒýÆðËÀÍöµÄÖ÷ÒªÔÒòÖ®Ò»¡£Òò´´ÉËÒýÆðµÄËÀÍöÓÐ39.5%·¢ÉúÔÚÔºÄÚ£¬¶ø×÷Ϊ´´É˺󲢷¢Ö¢µÄŧ¶¾Ö¢ÔòÊÇÒýÆðÔºÄÚËÀÍöµÄÖØÒª²¡Òò¡£ÈçÄܶԴ´É˺óŧ¶¾Ö¢½øÐÐÔçÆÚÔ¤²â£¬²¢¶Ô¸ßΣÉËÔ±½øÐÐÔçÆÚ¸ÉÔ¤ºÍÔçÆÚÖÎÁÆ£¬Ôò¿ÉÌá¸ß´´ÉËÉËÔ±µÄÔ¤ºó£¬¸ÄÉÆ´´ÉËÉËÔ±µÄ½á¾Ö¡£Ä¿Ç°£¬Ô¤²â´´É˺óŧ¶¾Ö¢·¢ÉúÖ÷ÒªÓÐÈýÖÖ·½·¨£ºµÚÒ»£¬ÀûÓÃÉúÎï±êÖ¾Îï½øÐÐÔ¤²â£»µÚ¶þ£¬ÀûÓÃÉËÔ±µÄÈË¿ÚѧÐÅÏ¢½øÐÐÔ¤²â£»µÚÈý£¬ÀûÓô´É˺óµÄËðÉËѧÐÅÏ¢½øÐÐÔ¤²â¡£µ«ÖÁ½ñÓÃÓÚÑéÖ¤ÕâЩ·½·¨Ô¤²âÄÜÁ¦µÄÏà¹ØÊµÑ鿪չ½ÏÉÙ£¬ÇÒʵÑé½áÂÛ´æÔÚÕùÒé¡£½ñºóÓ¦ÔÚ´´É˺óŧ¶¾Ö¢·¢Éú·½Ã濪չ¸üÈ«ÃæÉîÈëµÄ̽Ë÷£¬ÒÔѰÇó¸ü¼Ó¿ìËÙ¡¢×¼È·¡¢±ãÓÚʵʩµÄÔ¤²â·½·¨¡£ http://www.burnstrauma.com/article.asp?issn=2321-3868;year=2014;volume=2;issue=3;spage=106;epage=113;aulast=Jin 3. New strategy for sepsis: Targeting a key role of platelet-neutrophil interaction ŧ¶¾Ö¢ÖÎÁÆÐ²ßÂÔ£ºÃé×¼ÖÐÐÔÁ£Ï¸°ûºÍѪС°åµÄÏ໥×÷Óà ժҪ£ºÖÐÐÔÁ£Ï¸°ûºÍѪС°åÔÚÏÈÌìÐÔÃâÒß·´Ó¦ÖаçÑÝ×ÅÖØÒªµÄ½ÇÉ«£¬¶øÆäÔÚŧ¶¾Ö¢Ê±ÖÐËùÆð×÷ÓøüÊDz»ÈݺöÊÓ¡££¬Ä¿Ç°Å§¶¾Ö¢ÒýÆðѪС°åÒì³£»î»¯¼°ÖÐÐÔÁ£Ï¸°û¹¦ÄÜʧµ÷Òѱ»¹«ÈÏ¡£ÑªÐ¡°åÔÚŧ¶¾Ö¢ÖпɴٽøÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨DIC£©µÄÐγɣ¬²¢ÇÒ¿ÉÒÔ½øÒ»²½¼ÓÖØÑ×Ö¢·´Ó¦¡£¶øÅ§¶¾Ö¢ÒýÆðµÄÖÐÐÔÁ£Ï¸°û¹¦ÄÜʧµ÷Ö÷Òª±íÏÖΪ£ºÏò¸ÐÈ¾ÇøÓò¾Û¼¯ºÍÇ¨ÒÆÊÜ×裬ÔÚÔ¶¶ËÆ÷¹ÙÒì³£½þÈó£¬ÒÔ¼°ÖÐÐÔÁ£Ï¸°ûÇå³ýÑÓ³Ù¡£Ä¿Ç°£¬Ëæ×ŶÔÖÐÐÔÁ£Ï¸°ûºÍѪС°åÏ໥×÷ÓÃÑо¿µÄ²»¶ÏÉîÈ룬ÒѾ·¢ÏÖŧ¶¾Ö¢Ê±Á½ÕßµÄÏ໥×÷ÓÿÉÒÔ½øÒ»²½¼Ó¿ì²¢¼Ó֨ŧ¶¾Ö¢Ê±µÄÑ×Ö¢·´Ó¦¡£±¾Îļ´ÊÇ×ÅÑÛÓÚŧ¶¾Ö¢Ê±ÑªÐ¡°åµÄÒì³£»î»¯¡¢ÖÐÐÔÁ£Ï¸°ûµÄ¹¦ÄÜÒì³£ºÍÁ½Õß¼äµÄÏ໥×÷Óã¬¶ÔÆäÖеÄÏà¹Ø·Ö×Ó»úÖÆ¼°Á½ÖÖϸ°û¼äÏ໥¶Ô»°µÄ×÷Óýá¹û½øÐвûÊö£¬´Ó¶øÎªÅ§¶¾Ö¢µÄ¾ÈÖÎÌṩһÖÖеÄ˼·¡£ http://www.burnstrauma.com/article.asp?issn=2321-3868;year=2014;volume=2;issue=3;spage=114;epage=120;aulast=Wang 4. Current understanding of tyrosine kinase BMX in inflammation and its inhibitor ·ÇÊÜÌåÀÒ°±ËἤøBMXÔÚÑ×Ö¢ÖеÄ×÷Óü°ÆäÒÖÖÆ¼Á ÕªÒª£ºTec ¼Ò×åÊÇ·ÇÊÜÌåÀÒ°±Ëáµ°°×¼¤Ã¸µÄµÚ¶þ´ó³ÉÔ±£¬°üÀ¨TEC¡¢BTK¡¢ITK¡¢TXKºÍBMX¡£Tec¼Ò×å³ÉÔ±¼ä°±»ùËáÐòÁÐͬԴÐԽϸߣ¬¾ßÓÐÏàËÆµÄµ°°×Öʽṹ¡£BMX¼¤Ã¸£¨¹ÇËèX¼¤Ã¸£©×î³õÔÚÈ˹ÇËèϸ°ûÖб»·¢ÏÖ¡£³ýËèÑùÔìѪϸ°ûÍ⣬BMX¼¤Ã¸»¹·Ö²¼ÓÚÄÚÆ¤Ï¸°ûºÍ¶àÖÖÖ×Áöϸ°û¡£Ëæ×Å¶ÔÆä½á¹¹¹¦ÄܵIJ»¶ÏÈÏʶ£¬BMX¼¤Ã¸ÓëÑ×Ö¢¼°Ö×Áö·¢ÉúµÄ¹ØÏµÈÕÒæÊܵ½ÈËÃǵÄÖØÊÓ¡£±¾ÎľÍBMX¼¤Ã¸µÄ½á¹¹¡¢ÔÚÑ×Ö¢ÖеÄ×÷Óü°ÐźŻúÖÆ¡¢BMX¼¤Ã¸ÒÖÖÆ¼ÁµÈ×÷Ò»¼òÒª×ÛÊö¡£ http://www.burnstrauma.com/article.asp?issn=2321-3868;year=2014;volume=2;issue=3;spage=121;epage=124;aulast=Qiu 5. Evaluation of optimized continuous venovenous hemodiafiltration therapy efficiency in severe burn patients with sepsis ÓÅ»¯³ÖÐø¾²Âö-¾²ÂöѪҺ͸ÎöÂ˹ýÖÎÁÆÑÏÖØÉÕÉËŧ¶¾Ö¢ÁÆÐ§µÄÆÀ¹À ÕªÒª£º×÷Ϊʼ¶¯ÒòËØ£¬Å§¶¾Ö¢¼°Òòŧ¶¾Ö¢ËùÖµĶàÆ÷¹Ù¹¦Äܲ»È«×ÛºÏÕ÷£¨MODS£©ÊÇÉÕÉË»¼ÕßµÄÖ÷ÒªÖÂËÀÔÒò¡£ÔÚ±¾ÊÔÑéÖУ¬ÎÒÃǼì²âÁËÈëÑ¡ÑÏÖØÉÕÉËŧ¶¾Ö¢»¼ÕßÔÚÖÎÁƹý³ÌÖÐѪҺTNF-¦Á¡¢ IL-6 ºÍ IL-8µÄŨ¶ÈÒÔ¼°ÖÎÁÆÇ°ºÍÖÎÁÆ42hʱ»¼ÕßÉúÃüÌåÕ÷Ö¸±ê£¨ÐÄÂÊ¡¢ºôÎüƵÂÊ¡¢ÖÐÐľ²Âöѹ£©ºÍʵÑéÊÒ¼ì²éÖ¸±ê£¨°×ϸ°û¼ÆÊý¡¢ÑªÌÇ¡¢ÑªÄÆ¡¢ÑªÄòËØµª¡¢Ñª¼¡ôû£©µÄ±ä»¯¡£22ÃûÉÕÉËŧ¶¾Ö¢»¼Õß±»Ëæ»ú·ÖÈë¶ÔÕÕ×飨A×飩ºÍÊÔÑé×飨B×飩¡£A×黼Õß½ÓÊܳ£¹æÖÎÁÆ£¬B×黼Õß½ÓÊܳ£¹æÖÎÁÆ+³ÖÐø¾²Âö-¾²ÂöѪҺ͸ÎöÂ˹ýÖÎÁÆ£¨CVVHDF£©¡£ÖÎÁÆ42hʱ£¬B×黼ÕßÉúÃüÌåÕ÷Ö¸±êºÍʵÑéÊÒ¼ì²éÖ¸±ê½ÏA×黼ÕßµÄÏà¹ØÖ¸±êÃ÷ÏÔ½µµÍ£¬²îÒìÓÐͳ¼ÆÑ§ÒâÒå(P < 0.05)¡£ ÔÚÖÎÁÆÇ°ºÍÖÎÁƺó12h¡¢18h¡¢24h¡¢36hºÍ42h£¬·Ö±ð¼ì²â2×黼ÕßѪ½¬ÖÐTNF-¦Á¡¢IL-6ºÍIL-8Ũ¶È¡£½á¹ûÏÔʾ£¬ÓëÖÎÁÆÇ°±È½Ï£¬B×黼ÕßÔÚÖÎÁƺó18hѪ½¬TNF-¦ÁŨ¶ÈϽµ32%£¬42hʱϽµ43%£»ÔÚÏàӦʱÏàµã£¬A×黼ÕßѪ½¬TNF-¦ÁŨ¶È¸ßÓÚÖÎÁÆÇ°£¬ÇÒ¸ßÓÚÕý³£ÖµË®Æ½¡£ÓëÖÎÁÆÇ°±È½Ï£¬B×黼ÕßÔÚÖÎÁƺó18hѪ½¬IL-6Ũ¶È(0.274¡À0.137 ng/ml)Ã÷ÏÔϽµ£¬ÔÚÖÎÁƺó24hÂÔÓÐÉý¸ßºó³ÖÐø½µµÍÖ±µ½ÊÔÑéÖÎÁƽáÊø¡£ÓëÖÎÁÆÇ°±È½Ï£¬B×黼ÕßÔÚÖÎÁƺó18hhѪ½¬IL-8Ũ¶ÈϽµ56%£¬ÖÎÁƺó42hѪ½¬IL-8Ũ¶ÈϽµ70%£¬ÇÒ¾ù¸ßÓÚÕý³£ÖµË®Æ½(P < 0.01)¡£ A×é11ÃûÉÕÉË»¼ÕßÖÐÓÐ4ÈËËÀÍö£¬¶øB×é11ÃûÉÕÉË»¼ÕßÖнö1ÈËËÀÍö¡£×ÛÉÏ£¬³ÖÐø¾²Âö-¾²ÂöѪҺ͸ÎöÂ˹ýÖÎÁÆÄÜÓÐЧµØ½µµÍÉÕÉËŧ¶¾Ö¢»¼ÕßѪ½¬TNF-¦Á¡¢ IL-6 ºÍ IL-8µÄŨ¶È£¬²¢ÄܽµµÍMODSµÄ·¢²¡ÂÊ¡£ http://www.burnstrauma.com/article.asp?issn=2321-3868;year=2014;volume=2;issue=3;spage=125;epage=129;aulast=Xu |
» ²ÂÄãϲ»¶
ÖÊÁ£pACDK4-CÐòÁÐÇóÖú
ÒѾÓÐ0È˻ظ´
sigmaÖÊÁ£pACDK4-CÐòÁÐÇóÖú
ÒѾÓÐ0È˻ظ´
·¨Ò½Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ121È˻ظ´
ÇóÀíÂÛ¼ÆËãºÏ×÷
ÒѾÓÐ1È˻ظ´
3Ö§ATCCÔ´ú½ø¿Ú¾úÖê´ò°ü³ö
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
2014Äê¶ÈÕã½Ê¡×ÔÈ»¿ÆÑ§»ù½ðÄâ×ÊÖúÏîÄ¿Çåµ¥
ÒѾÓÐ14È˻ظ´
guolili9900
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 23 (СѧÉú)
- ½ð±Ò: 7314.3
- ºì»¨: 4
- Ìû×Ó: 735
- ÔÚÏß: 117.2Сʱ
- ³æºÅ: 2367334
- ×¢²á: 2013-03-22
- רҵ: Ö×ÁöÎïÀíÖÎÁÆ

2Â¥2014-08-14 10:50:06
myyounger
ÖÁ×ðľ³æ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 8 (Ó×¶ùÔ°)
- ¹ó±ö: 0.105
- ½ð±Ò: 23288.5
- É¢½ð: 500
- ºì»¨: 144
- Ìû×Ó: 16619
- ÔÚÏß: 484.6Сʱ
- ³æºÅ: 638546
- ×¢²á: 2008-10-28
- רҵ: ÄÔѪ¹Ü½á¹¹¡¢¹¦ÄÜÒì³£¼°Ïà
3Â¥2014-08-14 19:25:03














»Ø¸´´ËÂ¥